Publications by Pilot Project PIs

Grant Cycle III (2014-2018)

  1. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X.. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 2014 Jun 12;33(24):3140-50. PubMed PMID: 23851510
  2. Mostaghel EA, Lin DW. Practical guide to the use of abiraterone in castration resistant prostate cancer. Can J Urol. 2014 Apr;21(2 Supp 1):57-63. PubMed PMID: 24775725. PMCID: PMC4139288
  3. Mostaghel EA, Plymate SR, Montgomery B.Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res. 2014 Feb 15;20(4):791-8. PubMed PMID: 24305618; PubMed Central PMCID: PMC3944407.
  4. Mostaghel EA,Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Abiraterone in the treatment of metastatic castration-resistant prostate cancer.
  5. Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R, Nelson PS, Fang M. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.PLoS One. 2013;8(9):e74671. PubMed PMID: 24098661; PubMed Central PMCID: PMC3787014.
  6. Yu Y, Liu L, Xie N, Xue H, Fazli L, Buttyan R, Wang Y, Gleave M, Dong X.Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control.J Clin Endocrinol Metab. 2013 Jul;98(7):2887-96. PubMed PMID: 23666965. PMCID: PMC4078099

Grant Cycle II (2007-2013)

  1. Alumkal JJ, Herman JG. Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers. Cancer Discov. 2012 Nov;2(11):979-81. PMCID: PMC3661413
  2. Aslan JE, You H, Williamson DM, Endig J, Youker RT, Thomas L, Shu H, Du Y, Milewski RL, Brush MH, Possemato A, Sprott K, Fu H, Greis KD, Runckel DN, Vogel A, Thomas G. Akt and 14-3-3 control a PACS-2 homeostatic switch that integrates membrane traffic with TRAIL-induced apoptosis. Mol Cell 34:497-509; 2009. PMCID: PMC2744858.
  3. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon N, Wang H, Chen S, Balk SP. Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration Resistant Prostate Cancer and is Upregulated by Treatment with CYP17A1 Inhibitors. Cancer Res. 2011 Aug 25. [Epub ahead of print].
  4. FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 8:230; 2008. PMCID: PMC2519091.
  5. Knouf EC, Metzger MJ, Mitchell PS, Arroyo JD, Chevillet JR, Tewari M, Miller AD. Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J Virol 83:7353-6; 2009. PMCID: PMC2704771.
  6. Mostaghel EA, Lin DW, Amory JK, Wright JL, Marck BT, Nelson PS, Matsumoto AM, Bremner WJ, Page ST. Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. J Clin Endocrinol Metab. 2012 Aug;97(8):2809-17. PMCID: PMC3410271
  7. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50:298-301; 2010.
  8. Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL. Association of Caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. The Prostate 70:1020-35, 2010. PMCID: PMC2875326.
  9. Linsen SE, de Wit E, Janssens G, Heater S, Chapman L, Parkin RK, Fritz B, Wyman SK, de Bruijn E, Voest EE, Kuersten S, Tewari M, Cuppen E. Limitations and possibilities of small RNA digital gene expression profiling. Nat Methods 6:474-6; 2009. NIHMS292819
  10. Liu G, Atteridge CL, Lundgren AD, Wang X, Wu JD. The membrane type matrix metalloproteinase MMP14 mediates shedding of MICA independent of ADAMs. J Immunol 184:3346-50; 2010.
  11. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, Tewari M, Liu A, Vessella R, Rostomily R, Born D, Horwitz M, Ware C, Blau CA, Cleary MA, Rich JN, Ruohola-Baker H. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71:4640-52; 2011. PMCID: PMC3129496.
  12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513-8; 2008. PMCID: PMC2492472.
  13. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9:237-49; 2009. PMCID: PMC2921605.
  14. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68:861-71; 2008.
  15. Morrissey C, Dowell A, Koreckij TD, Nguyen H, Lakely B, Fanslow WC, True LD, Corey E, Vessella RL. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 70:1799-808; 2010. PMCID: PMC3104406.
  16. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-41; 2007.
  17. Mostaghel EA, Marck B, Plymate S, Vessella RL, Balk SP, Matsumoto AM, Nelson PS, Montgomery B. Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011 Aug 1. [Epub ahead of print]. NIHMS314872.
  18. Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res 14:5769-77; 2008.
  19. Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, Amory JK, Nelson PS, Matsumoto AM. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab 96:430-7; 2011. PMCID: PMC3048323.
  20. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 69:5568-74; 2009. PMCID: PMC2884104.
  21. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol 179:400-10; 2011.
  22. Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R, Nelson PS, Fang M. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS One. 2013 Sep 30;8(9):e74671. PMCID: PMC3787014
  23. Qu X, Randhawa G, Friedman C, O’Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. Cancer Genet. 2013 Jan-Feb;206(1-2):1-11. PMCID: PMC3632390
  24. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60:1238-43. PMCID: PMC2095486.
  25. Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R, Fisher PB, Plymate SR, Wu JD. IL-6 promotes prostate tumorgenesis and progression through autocrine cross-activation of IGF-IR. Oncogene 30:2345-55; 2011. PMCID: PMC3112005.
  26. Roth MY, Page ST. A role for dihydrotestosterone treatment in older men? Asian J Androl 13:199-200; 2011.
  27. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375:1437-46; 2010. PMCID: PMC2948179.
  28. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715-30; 2010. PMCID: PMC2912187.
  29. Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Trans Med 3:85ra47; 2011.
  30. Vermulst M, Bielas JH, Kujoth GC, Ladiges WC, Rabinovitch PS, Prolla TA, Loeb LA. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet 39:540-3; 2007.
  31. Vermulst M, Wanagat J, Kujoth GC, Bielas JH, Rabinovitch PS, Prolla TA, Loeb LA. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet 40:392-4; 2008.
  32. Wang X, Lundgren AD, Singh P, Goodlett DR, Plymate SR, Wu JD. An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit shedding. Biochem Biophys Res Commun 387:476-81; 2009. PMCID: PMC2737406.
  33. Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL, Mostaghel EA. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SCLO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev 20:619-27; 2011. PMCID: PMC3073610.
  34. Wu JD, Atteridge K, Wang X, Seya T, Plymate SR. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res 15:632-40; 2009. PMCID: PMC2775521.
  35. Wu JD, Lin DW, Page ST, Lundgren AD, True LD, Plymate SR. Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. Transl Oncol 2:39-45; 2009. PMCID: PMC2647701.
  36. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Feedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW. SLCO2B1 and SLCO1B3 as pharmacogenomic determinants of resistance to androgen deprivation therapy in prostate cancer. J Clin Oncol 29:2565-73, 2011. PMCID: PMC3138634.
  37. You H, Thomas G. A homeostatic switch in PACS-2 links membrane traffic to TRAIL-induced apoptosis. Cell Cycle 8:2679-80; 2009.
  38. Youker RT, Shinde U, Day R, Thomas G. At the crossroads of homoeostasis and disease: roles of the PACS proteins in membrane traffic and apoptosis. Biochem J 421:1-15; 2009.
  39. Yu EY, Mankoff DA. Positron emission tomography imaging as a cancer biomarker. Expert Rev Mol Diagn 7:659-72; 2007.
  40. Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, Mankoff DA. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 36:192-8; 2011. PMCID: PMC3129631.
  41. Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, Fazli L, Cox M, Plymate S, Gleave M, Dong X. Prostate stromal cells express the progesterone receptor to control cancer cell mobility. PLoS One. 2014 Mar 24;9(3):e92714. PMCID: PMC3963951
  42. Yu Y, Liu L, Xie N, Xue H, Fazli L, Buttyan R, Wang Y, Gleave M, Dong X. Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. J Clin Endocrinol Metab. 2013 Jul;98(7):2887-96. PMID: 23666965

Grant Cycle I (2001-2006)

  1. Friedrichsen DM, Stanford JL, Isaacs SD Maner M, Chang BI, Deutsch K, Gillanders E, Kolb S, Wiley KE, Badzioch MD, Zheng SL, Walsh PC, Jarvik GP, Hood L, Trent JM, Isaacs WB, Ostrander EA, Xu J.  Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. PNAS 2004; 101(7):1939-1944.
    PMID: 14769943
  2. Knudsen BS, Lucas JM, Fazli L et al. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathology 2005;167(1):255-66.
    PMID: 15972969
  3. Bland LB, Garzotto M, DeLoughery TD, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, and Beer TM. Phase II Study of Transdermal Estrogen in Androgen-Independent Prostate Cancer.  Cancer, 103:717-23, 2005.
    PMID: 15641029
  4. Beer TM, Bland LB, Bussiere JR, Neiss M, Wersinger EM, Garzotto M, Ryan CW, and Janowsky JS. Testosterone loss and estradiol administration modifies memory in men, Journal of Urology, 175(1):130-5, 2006.
    PMID: 16406889
  5. Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, and Beer TM.  Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer.  Journal of Lipid Research, 47(2):349-55, 2006.
    PMID: 16299398
  6. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Goehle S, Kollipara R, DePinho R, Simon J, Bedalov A. Antitumor activity of a small molecule inhibitor of human Sir2 enzymes. Cancer Res 2006;15;66(8):4368-77.
    PMID: 16618762
  7. Tavassoli P, Snoek R, Ray M, Rao LG, Rennie PS. Rapid, non-destructive, cell-based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells. Prostate 2007 Mar 1;67(4):416-26.
    PMID: 17219378
  8. Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM., Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer 2007 Sep 1;110(5):996-1002.
    PMID: 17639587